Blood samples reveal secrets of drug resistance in KRAS cancers
NCT ID NCT05272423
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 25 times
Summary
This study collects blood samples from up to 500 adults across the US who have KRAS G12C cancer that stopped responding to targeted drugs like sotorasib or adagrasib. Participants provide a simple blood draw at a local lab, and researchers analyze the samples to find genetic changes that cause resistance. No new treatment is given—the goal is to learn how resistance develops in different cancers and drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS P.G12C are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.